Search Results
Your search for The ASCO Post ,The ASCO Post matches 16992 pages
Showing 1701 - 1750
Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with ...
John V. Heymach, MD, PhD, on NSCLC: New Data on Durvalumab Plus Chemotherapy From the AEGEAN Trial
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the AEGEAN trial, which showed that patients with treatment-naive, resectable, non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant...
IMbrave050: Recurrence-Free Survival With Adjuvant Atezolizumab Plus Bevacizumab for HCC
Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to results from the phase III IMbrave050 clinical trial, which were presented by Chow et al at the American...
NIH Study Outlines Opportunities to Achieve Cancer Moonshot Goal of Reducing Cancer Mortality in the United States
Researchers from the National Institutes of Health (NIH) have outlined opportunities for achieving President Joe Biden and First Lady Jill Biden’s Cancer Moonshot national goal of reducing the cancer death rate by at least 50% over the next 25 years. A study published by Shiels et al in Cancer...
Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma
Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by Kendra et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract...
Personalized mRNA-Based Cancer Vaccine Plus Pembrolizumab for High-Risk Melanoma
mRNA-4157/V940, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor pembrolizumab improved recurrence-free survival compared with pembrolizumab alone in patients with high-risk melanoma, and clinical benefit was observed regardless of tumor mutational...
First-Line Pembrolizumab Plus Gemcitabine/Cisplatin May Improve Overall Survival in Advanced Biliary Tract Cancer
The addition of pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial, which were presented by Robin Katie Kelley, MD, and colleagues at the...
Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable NSCLC: AEGEAN Trial
Treatment-naive patients with resectable non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response compared with those who received neoadjuvant chemotherapy alone,...
Mitesh J. Borad, MD, on Hepatobiliary Cancers: Management Updates
Mitesh J. Borad, MD, of the Mayo Clinic Comprehensive Cancer Center, discusses the expanding number of options in immunotherapies for patients with advanced hepatobiliary cancers, applying targeted treatments to this disease, and the importance of genomic profiling in patients with biliary tract...
Shannon N. Westin, MD, MPH, on Ovarian Cancer: Results From the NOW Trial of Neoadjuvant Olaparib in BRCA-, PALB-, or RAD51C–Mutant Disease
Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses results from the NOW study, which showed that neoadjuvant olaparib is feasible and has a good safety profile in patients with mutated, advanced-stage ovarian cancer. Even in patients with stage IV disease,...
Shannon N. Westin, MD, MPH, on Endometrial and Ovarian Cancers: New Data on Selumetinib and Olaparib From the SOLAR Trial
Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses new findings on the combination of olaparib and selumetinib, which benefited patients with RAS-mutant ovarian and endometrial cancers. This combination will be explored further in these select cohorts in the ...
NCCN 2023 Annual Conference: Quality-of-Life Issues
The National Comprehensive Cancer Network (NCCN) held its annual meeting recently in Orlando. On this week’s episode of <em>The ASCO Post Podcast</em>, we’ll hear from two presenters who discussed quality of life issues in individuals with cancer.
Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States
AbbVie announced that it intends to voluntarily withdraw, in the United States, accelerated ibrutinib (Imbruvica) approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy as well as patients with marginal zone lymphoma (MZL) who require systemic therapy...
Pragmatica-Lung Trial Begins Enrolling Patients With NSCLC Who Did Not Respond to Previous Therapy
The National Cancer Institute (NCI) announced that it has helped launch the randomized phase III Pragmatica-Lung trial examining the efficacy of ramucirumab plus pembrolizumab in treating patients with advanced non–small cell lung cancer (NSCLC). The new study is one of the first NCI-supported...
New Study Examines Cancer-Related Mortality Rates During First Year of COVID-19 Pandemic
U.S. mortality rates with cancer as the underlying or primary cause decreased during the first year of the COVID-19 pandemic, whereas mortality rates with cancer as a contributing cause increased, according to a new study published by Zhao et al in JCO Oncology Practice. The findings demonstrated...
Digital Breast Tomosynthesis May Improve Breast Cancer Screening Performance in Community Settings
Researchers have found that digital breast tomosynthesis may have improved breast cancer screening performance in community practices and could be effective at identifying more invasive cancers compared with digital mammography, according to a new study published by Lee et al in Radiology. The...
Statewide Survey May Provide Insight Into Cancer-Related Knowledge, Beliefs, and Behaviors of Hispanic Individuals in Indiana
A new survey of Hispanic adults residing in Indiana may present a snapshot of their cancer-related knowledge, beliefs, and behaviors and provide guidance for the future development of tailored cancer screening messaging and prevention strategies, according to a study published by Espinoza-Gutarra...
Novel Device May Be Safe, Effective Chemotherapy Delivery System for Patients With Muscle-Invasive Bladder Cancer Who Are Unfit for Standard Therapy
Researchers have found that the novel intravesical chemotherapy delivery system TAR-200 may be safe and effective for patients with advanced muscle-invasive bladder cancer who are medically unfit for standard treatment, according to a new study published by Tyson et al in The Journal of Urology....
Financial Toxicity of Cancer May Impact Partner’s Quality of Life
Researchers have discovered that the financial impact of an individual’s cancer diagnosis may also impact a partner’s health-related quality of life, according to a new study published by Ghazal et al in JAMA Network Open. “When you think of key developmental milestones young adults expect to...
Arlene O. Siefker-Radtke, MD, on Urothelial Cancer: Emerging Therapies
Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, provides an overview of the emerging treatments for urothelial cancer, including several new agents in the antibody-drug conjugate and tyrosine kinase inhibitor classes. She describes the clinical activity and...
Prior CTLA-4 Inhibition May Influence Response to PD-1 Inhibitors in Patients With Advanced Melanoma
Researchers have found that responses to PD-1 inhibitor treatment in patients with advanced melanoma may depend on whether they had received previous treatment with CTLA-4 inhibitors, according to a new study published by Campbell et al in Cancer Cell. “In our large set of data, features that have...
Combination Therapy May Help Patients With KMT2A-Mutated ALL or AML Overcome BET Inhibitor Resistance
Researchers have developed a novel combination therapy approach to help patients with KMT2A-mutated acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) overcome resistance to bromodomain and extraterminal domain (BET) inhibitors without adding toxicity, according to a novel study...
Azacitidine in Combination With Trametinib May Be Effective for Pediatric Patients With JMML
Researchers have found that the hypomethylating agent azacitidine plus the MEK inhibitor trametinib may be a promising new combination to treat patients with juvenile myelomonocytic leukemia (JMML), according to a preclinical study published by Pasupuleti et al in Molecular Therapy. Background JMML ...
Healthy Lifestyles May Be Associated With Reduced Mortality Risk in Pediatric Cancer Survivors
Researchers have provided strong evidence that a healthy lifestyle may significantly reduce mortality in adults who have survived pediatric cancer, according to a new study published by Dixon et al in The Lancet. The findings are among the first to reveal that the specific primary causes of...
Researchers Identify Potential Biomarkers of Response to Immunotherapy in Patients With Renal Cell Carcinoma
Researchers have revealed that the number of tumor-infiltrating lymphocytes, the state of necrosis, and mutations to the tumor-suppressor gene PBRM1 form a biomarker signature that may predict how patients with renal cell carcinoma will respond to immunotherapy, according to a novel study published ...
USPSTF Announces New Leadership
The U.S. Preventive Services Task Force (USPSTF) recently announced the appointments of Michael J. Barry, MD, as Chair, and Michael Silverstein, MD, MPH, as Vice Chair. Wanda K. Nicholson, MD, MPH, MBA, will remain in her role as Vice Chair. Dr. Barry will assume the role of Chair from Carol M....
City of Hope to Rebrand Cancer Treatment Centers of America Locations to Reflect Transition to National System
City of Hope in Duarte, California, recently announced that its subsidiary, Cancer Treatment Centers of America (CTCA), will fully transition its clinical locations to City of Hope’s brand. CTCA locations in different cities will now be called City of Hope Atlanta, City of Hope Chicago, and City of ...
Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’
In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....
Elizabeth M. Jaffee, MD, FAACR, to Receive 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) will honor Elizabeth M. Jaffee, MD, FAACR, AACR Past President, with the 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the 2023 AACR Annual Meeting, to be held on April 14–19 in Orlando,...
Nobel Laureate Carolyn R. Bertozzi, PhD, to Receive 2023 AACR Award for Outstanding Achievement Cancer Research
The American Association for Cancer Research (AACR) will honor Nobel Laureate Carolyn R. Bertozzi, PhD, with the 2023 AACR Award for Outstanding Achievement in Chemistry in Cancer Research during the 2023 AACR Annual Meeting on April 14–19 in Orlando, Florida. Dr. Bertozzi’s award lecture will be...
Genetics Likely Caused My Small Cell Lung Cancer
When I was diagnosed with lung cancer, in 2007, I asked the physician not to tell me the type, stage, or prognosis. I was about to start nursing school and was aware enough about the disease to know that not many people survived. I’ve since discovered that I had stage 3B small cell lung cancer,...
Heavy Toll From Prior Authorization Exceeds Alleged Benefits, According to AMA Survey
The approval process health insurers impose on medical services or drugs is generating a toll that exceeds the purported benefits, according to a physician survey recently released by the American Medical Association (AMA) and shared in a letter to federal health officials.1 Although health...
Kerin Adelson, MD, Named MD Anderson Chief Quality and Value Officer
The University of Texas MD Anderson Cancer Center has announced the appointment of Kerin Adelson, MD, as the institution’s Chief Quality and Value Officer. An accomplished clinician and researcher with extensive leadership experience in cancer care, Dr. Adelson will also hold a faculty appointment...
Lymphoma Research Foundation Establishes Kanti R. Rai, MD, Clinical Scholar Program for the Ongoing Study of CLL
The Lymphoma Research Foundation (LRF) has announced the creation of the Kanti R. Rai, MD, Clinical Scholar Program to fund the ongoing study of lymphoma and chronic lymphocytic leukemia (CLL). Established in recognition of the global leadership of Kanti R. Rai, MD, in the field of lymphoma and CLL ...
Two Cancer Experts to Head New Tisch Cancer Hospital at Mount Sinai Hospital
Two cancer experts have been named to lead Mount Sinai’s new Tisch Cancer Hospital, which is under development and expected to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been...
Study Examines Utility, Accuracy of ChatGPT in Offering Breast Cancer Screening Recommendations
A new study suggests that the answers generated by the artificial intelligence (AI) chatbot ChatGPT may provide correct breast cancer screening advice the vast majority of the time; however, the information is sometimes inaccurate or even fictitious, according to the report published by Haver et al ...
Interferon Alfa-2b May Substantially Increase Survival in Patients With Lymphomatoid Granulomatosis
Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...
Training Oncology Nurses on Primary Palliative Care May Improve End-of-Life Care and Spur Creation of Advance Directives for Patients With Cancer
Specially trained oncology infusion room nurses may be capable of improving advance care planning for patients with advanced cancer at the end of life, according to a new study published by Cohen et al in JNCCN—Journal of the National Comprehensive Cancer Network. Background “Advance care planning...
Addressing Health Disparities in Oncology Care—Legally and Ethically
A health disparity is typically defined as involving a differential in health outcomes between some groups of patients and other groups, for example, between White and Black patients, in which some groups fare better than others. Health inequities are commonly defined as health differences that...
Elena Ratner, MD, MBA on Sexual Identity and Function in Cancer Survivors
Elena Ratner, MD, MBA, of Yale Cancer Center/Smilow Cancer Hospital, discusses sexuality, intimacy, fertility, and menopause as important aspects of women’s cancer survivorship and the many effects of treatment on these issues. They often go unacknowledged in the medical community, Dr. Ratner says, ...
Ella A. Kazerooni, MD, on Lung Cancer Screening: Benefits and Challenges
Ella A. Kazerooni, MD, of the University of Michigan Rogel Cancer Center, discusses reducing cancer deaths in the United States by identifying patients at risk for lung cancer. Engaging with primary care physicians and facilitating referrals are keys to a successful lung cancer screening program,...
Jordan McPherson, PharmD, MS, BCOP, on Managing Immunotherapy-Related Toxicities
Jordan McPherson, PharmD, MS, BCOP, of the Huntsman Cancer Institute at the University of Utah, summarizes a case-based panel discussion on best practices in caring for patients with immune-related adverse events. He focuses on pneumonitis, which can occur with immune checkpoint inhibitor therapy, ...
NCCN Names UChicago Medicine Comprehensive Cancer Center as 33rd Member Institution
The National Comprehensive Cancer Network (NCCN) announced that the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) has been named its newest member institution. With the addition, there are now 33 academic centers across the United States that have multidisciplinary subject...
Deductibles, Copays May Discourage Patients From Receiving Follow-up Breast Cancer Screenings
Researchers found that 20% of patients attending breast cancer screening appointments were likely to skip additional testing after abnormal findings on their mammograms if there was a deductible or copayment involved, according to a new study published by Ngo et al in Radiology. Background...
HHS Releases National Cancer Plan to Advance the Goals of the Cancer Moonshot and Improve Outcomes for All Patients
On April 3, the U.S. Department of Health and Human Services (HHS) released a National Cancer Plan, which calls for collaboration to realize the objectives laid out in the Cancer Moonshot to reduce cancer mortality by at least 50% over the next 25 years and “end cancer as we know it.” Developed by...
FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv/Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
On April 3, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the antibody-drug conjugate enfortumab vedotin-ejfv (Padcev) in combination with the PD-1 inhibitor pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are...
Deborah M. Stephens, DO, on CLL/SLL: NCCN Clinical Practice Guidelines in Oncology® Update
Deborah M. Stephens, DO, of the Huntsman Cancer Institute at the University of Utah, discusses NCCN’s updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr. Stephens details the key factors in selecting front-line and subsequent...
Mandi L. Pratt-Chapman, PhD, on Oncology Care in the LGBTQI+ Community: Best Practices for Addressing Health Needs
Mandi L. Pratt-Chapman, PhD, of the George Washington University Cancer Center, discusses the specific health-care needs for cancer screening, treatment, and survivorship among members of the LGBTQI+ community. Because clinical practices and research studies do not routinely collect sexual...
Pathologic Complete Responses May Be Prognostic of Outcomes for Patients With Soft-Tissue Sarcoma
Researchers have discovered that pathologic complete responses may be associated with improved survival outcomes for patients with localized soft-tissue sarcoma who received preoperative chemoradiotherapy or radiotherapy, according to a novel study published by Wang et al in JAMA Oncology. The new...
More U.S. Patients With Prostate Cancer May Be Electing for Active Surveillance
Since 2010, investigators have discovered that the number of patients with prostate cancer in the United States who are choosing active surveillance over surgery or radiation therapy may be rapidly increasing, according to a new study published by Al Awamlh et al in JAMA Internal Medicine....
